Review
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Meta-Anal. Nov 28, 2019; 7(9): 406-417
Published online Nov 28, 2019. doi: 10.13105/wjma.v7.i9.406
Treatment of early stage (T1) esophageal adenocarcinoma: Personalizing the best therapy choice
Lindsay Danielle Kumble, Elisabeth Silver, Aaron Oh, Julian A Abrams, Joshua R Sonett, Chin Hur
Lindsay Danielle Kumble, Elisabeth Silver, Aaron Oh, General Medicine, Columbia University Medical Center, New York, NY 10032, United States
Julian A Abrams, Joshua R Sonett, Chin Hur, Department of Medicine, Columbia University Medical Center, New York, NY 10032, United States
Author contributions: Oh A, Silver E, and Kumble LD performed research; Abrams JA, Sonett JR, Hur C edited and provided feedback for the manuscript; Kumble LD, Silver E wrote the paper.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Chin Hur, MD, Doctor, Department of Medicine, Columbia University Irving Medical Center, 622 W. 168th Street, Presbyterian Hospital 9-105, New York, NY 10032, United States. ch447@cumc.columbia.edu
Telephone: +1-646-3173533 Fax: +1-212-3051081
Received: August 9, 2019
Peer-review started: August 9, 2019
First decision: September 19, 2019
Revised: October 3, 2019
Accepted: October 20, 2019
Article in press: October 20, 2019
Published online: November 28, 2019
Core Tip

Core tip: This paper is an important source of information for patients and clinicians faced with a diagnosis of T1b esophageal adenocarcinoma (T1b EAC). This paper explores and then outlines the potential benefits and risks of the numerous treatment options for T1b EAC, highlighting the integral role a patient’s individual wishes and values play into making a treatment decision that achieves the greatest outcome for that patient. The review advocates for further research regarding the effects of T1b EAC treatment options on a patient’s quality of life.